ADMA Biologics, Inc. (ADMA): Total Liabilities
$146.92M
As of 2025-12-31
$276.00M
As of 2026-06-30
-9.2%
3-year compound annual growth
+4.2%
5-year compound annual growth
+20.4%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $146.92M | +5.2% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $139.66M | -28.0% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $193.98M | -1.3% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $196.49M | +45.5% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $135.08M | +13.1% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $119.42M | +18.4% | 2022-03-24, Balance as of period end |
| 2019-12-31 | $100.90M | +46.0% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $69.11M | +2.1% | 2020-03-13, Balance as of period end |
| 2017-12-31 | $67.69M | +140.5% | 2019-03-13, Balance as of period end |
| 2016-12-31 | $28.14M | +22.9% | 2018-03-29, Balance as of period end |
| 2015-12-31 | $22.89M | +8.9% | 2017-02-24, Balance as of period end |
| 2014-12-31 | $21.01M | +101.9% | 2016-03-23, Balance as of period end |
| 2013-12-31 | $10.41M | +69.7% | 2015-03-09, Balance as of period end |
| 2012-12-31 | $6.13M | +141.4% | 2014-03-28, Balance as of period end |
| 2011-12-31 | $2.54M | n/a | 2013-03-06, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $146.92M | +5.2% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $218.73M | +43.5% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $686.24M | +5.8% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $114.23M | +4.4% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $168.90M | +19.3% |
| Repligen Corp (RGEN) | 2025-12-31 | $843.57M | -1.6% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $633.31M | -34.5% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $287.74M | -14.6% |
| Vericel Corp (VCEL) | 2025-12-31 | $133.33M | -5.3% |
Compare ADMA, TARS, IMCR, KRYS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗